Lynkuet, a dual neurokinin receptor antagonist, showed meaningful reductions in hot flush frequency and severity in postmenopausal women and breast cancer patients in clinical trials.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/women-can-expect-hot-flush-relief-following-ema-greenlight-2025a1000p78?src=rss
Author :
Publish date : 2025-09-22 15:07:00
Copyright for syndicated content belongs to the linked Source.
